Closed · W81XWH-14-PCRP-PSIA · CFDA 12.420 · Discretionary

DoD Prostate Cancer Population Science Impact Award

Federal grant opportunity posted by Defense Health Agency Contracting Activity - DHACA, cataloged on Grants.gov.

Varies
Award range
Closed
Status
October 29, 2014
Close date
3
Expected awards

The verdict

DoD Prostate Cancer Population Science Impact Award is a closed discretionary listing from Defense Health Agency Contracting Activity - DHACA that offered Varies by applicant across 3 expected awards. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 1,795 other opportunities from Defense Health Agency Contracting Activity - DHACA.

Varies
award range
Closed
application status
3
expected awards
12.420
CFDA program

Archived opportunity record

DoD Prostate Cancer Population Science Impact… is closed (last close October 29, 2014). Check the agency catalog for replacement NOFOs. Defense Health Agency Contracting Activity - DHACA still indexes 1,795 other opportunities here.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed October 29, 2014

Posted May 30 Closes Oct 29

Est. Total Funding

$3,600,000

Expected Awards

3

Instrument

Grant

Description

The PCRP Population Science Impact Award mechanism was first offered as the Population-Based Idea Development Award in FY09 and the Population-Based Research Award in FY10 and FY11. Since then, 62 applications have been received, and 4 have been recommended for funding. The Population Science Impact Award mechanism supports high-impact, population science approaches to prostate cancer research. Applications should clearly demonstrate the potential of the study to contribute significantly to the elimination of death from prostate cancer and/or enhancing the well-being of men experiencing the impact of the disease. As such, studies should address one of the PCRP overarching challenges, or, alternatively, justify the study as addressing another critical area in prostate cancer research. In addition, studies are expected to address one or more of the PCRP focus areas; for the Population Science Impact Award, projects focused on the following are particularly encouraged: genetics/genomics and biomarkers, especially those relevant to the early detection of aggressive disease, prognosis, and treatment response; survivorship and palliative care; and health disparity. The overall goal of this award is to generate data and/or tools that can only be achieved from the perspective of systematic studies focused on specific populations of individuals, rather than specific individuals. Such studies will be built upon the logic, concepts, and methods of one or more population sciences including but not limited to: • Epidemiology • Surveillance • Health services research • Outcomes research • Behavioral science • Social science • Dissemination research The outcomes for research supported through this award mechanism will have the potential for substantial impact for men with or at risk for prostate cancer within, for example, epidemiologic cohorts, defined communities, or health systems. Applications may propose retrospective, prospective, case control, cohort, or other population science study designs (including the use of biospecimens and data from established retrospective databases), provided that the study population is of sufficient size to provide appropriate statistical power. The study should address a well-developed hypothesis that is conceptually sound and specific for prostate cancer. The epidemiologic and/or biostatistical expertise of the study team should be clearly described and evident in the study plan. Applicants are expected to provide documentation demonstrating access to, and ability to recruit, the appropriate population(s), patient samples, and/or datasets in numbers sufficient to achieve robust statistical significance. Research involving human subject use is permitted under this funding opportunity; however, clinical trials will be supported only if they are determined to be no greater than minimal risk by the local Institutional Review Board (IRB) of record and the U.S. Army Medical Research and Materiel Command (USAMRMC) Office of Research Protections (ORP), Human Research Protection Office (HRPO). For example, a behavioral clinical trial with a prospective accrual of patients where a behavioral intervention (i.e., cohort or case-controlled study) has been designed to determine the outcome (testing instrument, study tool, hazard, etc.) with respect to exploratory information, safety, or effectiveness may be allowed if it is no greater than minimal risk as determined by the local IRB of record and HRPO. Clinical trials involving prospective accrual of patients to test a device, drug, biologic, or surgical procedure for a measurable outcome with respect to exploratory information, safety, effectiveness, and/or efficacy will not be supported by this award mechanism. Correlative studies associated with a clinical trial testing a device, drug, biologic, or surgical procedure are permitted if it is determined to be no greater than minimal risk by the local IRB of record and HRPO. A correlative study is defined as a prospective or retrospective collection of human anatomical substances (e.g., tissue, blood, nail clippings, bone marrow, behavioral documentation, other) to be used in research to answer a question regarding the disease, injury or condition, and/or intervention. It does not include the direct assessment of the outcome of any intervention for the prevention, diagnosis, treatment, or evaluation of the quality of life of the patient. Human subject research qualifying as greater than minimal risk will not be supported by this award mechanism.

Catch-all / unrestricted eligibility mark · W81XWH-14-PCRP-PSIA

Grants.gov marks DoD Prostate Cancer Population Science Impact… with a catch-all / unrestricted eligibility code (Unrestricted / see official listing). Read the official announcement text for the real applicant filter — the code alone is not a door list. The extract does not mark applicant cost-sharing as required. Instrument: Grant. Funding-activity code maps to Science and Technology / R&D (ST). This eligibility-code string dominates the Defense Health Agency Contracting Activity - DHACA book (1,791 peers, 100% of 1,796).

Code 99
Unrestricted / see official listing

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

CDMRP Help Desk 301-682-5507

What to do next

DoD Prostate Cancer Population Science Impact… is closed; use the parent program and agency catalog for the next funding cycle.

  • Browse open federal opportunities in the same category when this listing is closed. Open opportunities
  • Look up CFDA 12.420 across all indexed listings before you commit to this opportunity alone. Eligibility finder
  • Compare award ranges across federal categories before you pick a single CFDA. All categories

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants